Clinical trial
Comparative Study of Oestradiol Suppression: Zoladex 10.8mg/3 Month vs…
NCT00303524 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00303524 |
|---|---|
| Title | Comparative Study of Oestradiol Suppression: Zoladex 10.8mg/3 Month vs. 3.6mg/Month in ER +ve EBC Pre-menopausal Patients |
| Official title | An Open-label, Randomized, Parallel Group, Multicentre Study to Compare Oestradiol Suppression Between ZOLADEX 10.8 mg Depot Given 3 Monthly and ZOLADEX 3.6 mg Depot Given Monthly in Pre-menopausal Patients With ER Positive Early Breast Cancer |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Goserelin acetate |
| Enrollment | 170 |
| Start date | Feb 1, 2006 |
| Primary completion | Aug 1, 2007 |
| Completion | Feb 1, 2009 |
| First posted | Mar 17, 2006 |
| Last update posted | Dec 23, 2009 |
| Countries | Japan |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: